Table 1.
Published biological therapies in TETs.
| Trial | Agent | Target | N | ORR (%) (CR + PR) | TTP (months) | PFS (months) | Survival (months) |
|---|---|---|---|---|---|---|---|
| Palmieri et al. (5) | Octreotide/lanreotide ± prednisone | Somatostatin receptor | 16 | 6 (37) | 14 | NR | 15 |
| Thymoma | 10 | 4 (40) | NR | NR | NR | ||
| Thymic carcinoma | 3 | 1 (33) | NR | NR | NR | ||
| Loehrer et al. (6) | Octreotide ± prednisone | Somatostatin receptor | 38 | 12 (32) | NR | NR | NR |
| Thymoma | 32 | 12 (38) | 8.8 | NR | Not reached | ||
| Thymic carcinoma | 6 | 0 | 4.5 | NR | 23.4 | ||
| Giaccone et al. (7) | Belinostat | HDAC | 40 | 2 (5) | NR | NR | NR |
| Thymoma | 24 | 2 (8) | 11.4 | NR | Not reached | ||
| Thymic carcinoma | 16 | 0 | 2.7 | NR | 12.4 | ||
| Thomas et al. (8) | PAC–belinostat | HDAC | 13 | 7 (54) | NR | NR | NR |
| Thymoma | 7 | 5 (71) | NR | NR | NR | ||
| Thymic carcinoma | 6 | 2 (33) | NR | NR | NR | ||
| Rajan et al. (9) | Cixutumumab | IGF-1R | 49 | 5 (10) | NR | NR | NR |
| Thymoma | 37 | 5 (14) | 9.9 | NR | 27.5 | ||
| Thymic carcinoma | 12 | 0 | 1.7 | NR | 8.4 | ||
| Kurup et al. (10) | Gefitinib | EGFR | 26 | 1 (4) | 4 | NR | NR |
| Thymoma | 19 | NR | NR | NR | NR | ||
| Thymic carcinoma | 7 | NR | NR | NR | NR | ||
| Bedano et al. (11) | Erlotinib + bevacizumab | EGFR | 18 | 0 | NR | NR | NR |
| Thymoma | VEGF | 11 | 0 | NR | NR | Not reached | |
| Thymic carcinoma | 7 | 0 | NR | NR | Not reached | ||
| Thomas et al. (12) | Sunitinib | VEGFR | 35 | 4 (11) | NR | NR | NR |
| Thymoma | PDGFR | 16 | 1 (6) | NR | 5.5 | NR | |
| Thymic carcinoma | 19 | 3 (16) | NR | 6.2 | NR | ||
| Salter et al. (13) | Imatinib | KIT | 11 | 0 | NR | NR | NR |
| Thymoma | PDGFR | 0 | |||||
| Thymic carcinoma | 11 | 0 | NR | NR | NR | ||
| Giaccone et al. (14) | Imatinib | KIT | 7 | 0 | 2 | NR | 4 |
| Thymoma | PDGFR | 2 | 0 | 8.5 | NR | Not reached | |
| Thymic carcinoma | 5 | 0 | 1 | NR | 2 | ||
| Palmieri et al. (15) | Imatinib | KIT | 15 | 0 | NR | 3 | Not reached |
| Thymoma | PDGFR | 12 | 0 | NR | NR | NR | |
| Thymic carcinoma | 3 | 0 | NR | NR | NR | ||
| Wakelee et al. (16) | Saracatinib | SRC | 21 | 0 | NR | NR | NR |
| Thymoma | 14 | NR | NR | 3.4 | Not reached | ||
| Thymic carcinoma | 7 | NR | NR | 1.4 | Not reached |
NR, not reported.